[WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 24 ITEM 4A. UNRESOLVED STAFF COMMENTS 42 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 42 ITEM 6. DIRECTORS, SENIOR MANAGEMENT] [LIST OF SUBSIDIARIES Name Abbreviation Place of Incorporation WuXi AppTec (BVI) Inc. WXAT BVI British Virgin Islands WuXi AppTec Co., Ltd. WXAT PRC WuXi AppTec (Shanghai) Co., Ltd. WASH PRC Shanghai SynTheAll Pharmaceutical Co., Ltd. STA PRC WuXi AppTec (Suzhou) Co., Ltd. WASZ PRC WuXi AppTec (Tianjin) Co., Ltd. WATJ PRC WuXi AppTec Holding Company, Inc. WXAT Holding WuXi AppTec,] [Certification by the Chief Executive Officer I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Certification by the Chief Financial Officer I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer EX-13.1 5 d608038dex131.htm EX-13.1] [Certification by the Chief Financial Officer Edward Hu Chief Financial Officer EX-13.2 6 d608038dex132.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-182917 on Form S-8 of our reports dated April 15, 2014, relating to the consolidated financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc. and its subsidiaries, and the effectiveness of WuXi PharmaTech (Cayman) Inc. and its subsidiaries’ internal control]